Janux Therapeutics Nominates Development Candidate Under Collaboration, License Agreement With Bristol Myers Squibb

Janux Therapeutics, Inc. has nominated a development candidate under its collaboration and exclusive license agreement with Bristol Myers Squibb, which has triggered a $35 million milestone payment to Janux. The candidate targets a solid tumor antigen using Janux's TRACTr platform, and Janux will conduct preclinical development through IND submission, while Bristol Myers Squibb will manage clinical development and commercialization. Janux is also eligible for further milestone payments and tiered royalties on global sales.